Avineuro initiates Phase I clinical studies of Alzheimer's drug - Pharmaceutical Business review

07 Apr 2009

Avineuro initiates Phase I clinical studies of Alzheimer’s drug

Avineuro Pharmaceuticals has initiated the Phase I clinical studies of AVN-101, a potent small molecule for the treatment of Alzheimer's disease.

Avineuro said that the results of the Phase I studies are expected to be available in May 2009.

Based on these and other results, Avineuro Pharmaceuticals plans to advance AVN-101 into Phase II clinical trials in the second quarter of 2009.

Drug Discovery